Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups. (Q51779423)

12 April 2018

title

Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups. (English)

1 reference

12 April 2018

author

Brendon Chua

1

1 reference

12 April 2018

David Jackson

4

1 reference

12 April 2018

author name string

Weiguang Zeng

2

1 reference

12 April 2018

Yuk Fai Lau

3

1 reference

12 April 2018

language of work or name

English

0 references

publication date

31 July 2006

1 reference

12 April 2018

published in

Vaccine

1 reference

12 April 2018

volume

25

1 reference

12 April 2018

issue

1

1 reference

12 April 2018

page(s)

92-101

1 reference

12 April 2018

Challenges facing adjuvants for cancer immunotherapy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

The Toll-like receptor ligand MALP-2 stimulates dendritic cell maturation and modulates proteasome composition and activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Synthetic mycoplasma-derived lipopeptide MALP-2 induces maturation and function of dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Mycoplasma fermentans lipoprotein M161Ag-induced cell activation is mediated by Toll-like receptor 2: role of N-terminal hydrophobic portion in its multiple functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Differential recognition of structural details of bacterial lipopeptides by toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Recognition of lipopeptides by Toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Relationship between structures and biological activities of mycoplasmal diacylated lipopeptides and their recognition by toll-like receptors 2 and 6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Toll-like receptors and innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Toll-like receptors as adjuvant receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Identification of canine helper T-cell epitopes from the fusion protein of canine distemper virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Characterisation of the antibody response to a totally synthetic immunocontraceptive peptide vaccine based on LHRH.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

7 January 2021

Antifertility vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

New GnRH-like peptide construct to optimize efficient immunocastration of male pigs by immunoneutralization of GnRH.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Immunoneutralisation of gonadotrophin releasing hormone: a potential treatment for oestrogen-dependent breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Vaccines and passive immunological approaches for the control of fertility and hormone-dependent cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

The geometry of synthetic peptide-based immunogens affects the efficiency of T cell stimulation by professional antigen-presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Plasmodium falciparum polyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Protection of mice against SV40 tumours by Pam3Cys, MTP-PE and Pam3Cys conjugated with the SV40 T antigen-derived peptide, K(698)-T(708).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Totally synthetic lipid-containing polyoxime peptide constructs are potent immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Oral administration of an antigenic synthetic lipopeptide (MAP-P3C) evokes salivary antibodies and systemic humoral and cellular responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Dendritic Cell Immunotherapy of Hepatitis C Virus Infection: Toxicology of Lipopeptide-Loaded Dendritic Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.012

10.1016/J.VACCINE.2006.07.012

7 January 2021

Identifiers

DOI

1 reference

12 April 2018

PubMed ID

17055123

1 reference

12 April 2018